$IONS news
The latest IONS stock news: headlines, filings, AI summaries and sentiment for $IONS, updated around the clock.
- Ionis Lowers TRYNGOLZA Revenue Guidance and Delays Cash Flow Breakeven to 2029
- Ionis Reports Q3 2026 Revenue Growth Driven by DAWNZERA Amid TRYNGOLZA Launch Adjustments
- Ionis Pharmaceuticals Projects 2026 Revenue Between $875M and $900M Amid Lowered TRYNGOLZA Outlook
- Ionis Pharmaceuticals Shares Drop 27% Following Reduced Revenue Guidance for Tryngolza
- IONIS PHARMACEUTICALS INC - 10-Q Filing
- Ionis Pharmaceuticals Reports Third Quarter Earnings Beat on Strong Revenue Growth
- IONIS PHARMACEUTICALS INC - 8-K Filing
- Novartis to Halt Development of Ionis-Derived Heart Disease Therapy Following Clinical Trial Failure
- IONIS PHARMACEUTICALS INC - 8-K Filing
- Roche and Ionis Report Positive Late-Stage Trial Results for Kidney Drug
- IONIS PHARMACEUTICALS INC - 8-K Filing
- Ionis Pharmaceuticals Stock Falls Over 40% This Year Despite Analysts' Bullish Outlook
- Ionis Pharmaceuticals Stock Falls Over 40% This Year Despite Analysts' Bullish Outlook
- Novartis (NVS) and Ionis (IONS)' Experimental Cholesterol Drug Fails in Late-Stage Trial
- Novartis' Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- Novartis' Pelacarsen Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- BofA Sees Limited Impact from Novartis’ Pelacarsen Trial Failure, Citi Eyes Ionis
- Royalty Pharma's Pelacarsen Fails Phase 3 Trial; Focus Shifts to Spinraza Royalties
- Novartis Shares Fall After Key Clinical Trial Failures
- Ionis Pharmaceuticals Shares Drop After Pelacarsen Fails Key Phase 3 Heart Trial
- IONIS PHARMACEUTICALS INC - 8-K Filing
- Ionis Pharmaceuticals' Sell-Off Was Overdone Despite Clinical Setbacks
- IONIS PHARMACEUTICALS INC - 8-K Filing
- Ionis Pharmaceuticals' Sell-Off Was Overdone Despite Clinical Setbacks
- Ionis Pharmaceuticals Announces New Data for TRYNGOLZA, Reports Strong Q2 Revenue
- Alnylam Shares Drop After AstraZeneca Posts Negative Trial Data
- Ionis Pharmaceuticals Director Michael Hayden Purchases $1.1 Million Worth of Shares
- Ionis Pharmaceuticals Reports Q2 Revenue Growth Amid TRYNGOLZA Launch and Phase III Trial Outcome
- Investor Alert: Pomerantz Law Firm Investigates Ionis Pharmaceuticals for Potential Securities Fraud
- IONIS PHARMACEUTICALS INC - 10-Q Filing
- IONIS PHARMACEUTICALS INC - 8-K Filing
- AstraZeneca Reports Strong Q2 Earnings, Exceeds Expectations
- Arrowhead Reports Positive Late-Stage Trial Results for Lipid Drug, Impacting Rival Ionis Pharmaceuticals
- Cathie Wood Invests $15.3 Million in Ionis Pharmaceuticals Amid Stock Decline
- Cathie Wood Invests in Ionis Pharmaceuticals Amid Stock Decline
- Investor Alert: Pomerantz Law Firm Investigates Ionis Pharmaceuticals for Potential Securities Fraud
- AstraZeneca and Ionis Pharmaceuticals' Phase 3 Trial Failure Impacts Biotech Market Dynamics
- Morgan Stanley Raises Price Target for Alnylam Pharmaceuticals
- Biogen Shares Drop Following Mid-Stage Trial Results for Alzheimer’s Drug
- Biogen Shares Drop After Updated Data on Alzheimer's Drug Diranersen
- Ionis Pharmaceuticals Shares Drop Amid Failed Clinical Trial and Roche Partnership Exit
- AstraZeneca Shares Drop Sharply After Failed Heart Drug Trial
- AstraZeneca Shares Drop After Heart Disease Drug Fails Clinical Trial
- IONIS PHARMACEUTICALS INC - 8-K Filing
- BridgeBio Stock Surges Following AstraZeneca and Ionis' Failed Heart Drug Trial
- IONIS PHARMACEUTICALS INC - 8-K Filing
- IONIS PHARMACEUTICALS INC - 8-K Filing
- GSK and Ionis Report Positive Late-Stage Trial Results for Chronic Hepatitis B Drug
- Ionis Pharmaceuticals Q1 2026 Earnings Call Summary
- Ionis (IONS) Reports Q1 2026 Earnings with Strong Revenue Growth and Raised Guidance